FDA Approves Oralair to Treat Allergic Rhinitis

April 7, 2014
Melanie Sena

Melanie Sena is community editor of Pharmaceutical Technology.

FDA approves Oralair, the first sublingual allergen extract for the treatment of pollen allergies.

FDA

approved Oralair to treat allergic rhinitis with or without conjunctivitis that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the first sublingual allergen extract approved in the US.

Oralair is a once-daily tablet that dissolves after it is placed under the tongue. Oralair is started four months before the start of the grass pollen season and continued throughout the season. The first dose is taken at the health care provider’s office, where the patient is to be observed for at least 30 minutes for potential adverse reactions.

Oralair contains a mixture of freeze-dried extracts from the pollens of five grasses, including Kentucky Blue Grass, Orchard, Perennial Rye, Sweet Vernal and Timothy. Oralair is manufactured by Stallergenes S.A. of Antony, France.

Source:

FDA

Related Content:

PharmTech News